Common Contracts
2 similar Clinical Trial Research Agreement contracts
ContractClinical Trial Research Agreement • February 2nd, 2018
CLINICAL TRIAL RESEARCH AGREEMENT SMLOUVA O PROVEDENÍ KLINICKÉHO HODNOCENÍ This Clinical Trial Research Agreement (“Agreement”) is entered into as of 25 January 2018 and shall become effective upon the publishing of this executed Agreement in the Agreement Registry (“Effective Date”), by and among University Hospital Ostrava, with a place of business at 17. Listopadu 1790/5, 708 52 Ostrava-Poruba, Czech Republic, ID Number: 00843989, VAT Number: CZ00843989, TheFoundantion deed from 25th of November 1990, ref. OP- 054-25.11.90, In matters of this Agreement is authorized to act and sign: Josef Srovnal, M.D., deputy director for medical care, hereinafter called (“Institution”) and Prof. MUDr. Roman Hájek, CSc, with a place of business at University Hospital Ostrava, Hematooncology Clinic, 17.listopadu 1790, 708 52 Ostrava-Poruba, Czech Republic, hereinafter called (“Principal Investigator”) and Acerta Pharma B.V., with registered office at xxxxxxx, a Dutch limited liability company, rep
ContractClinical Trial Research Agreement • November 28th, 2017
CLINICAL TRIAL RESEARCH AGREEMENT SMLOUVA O PROVEDENÍ KLINICKÉHO HODNOCENÍ This Clinical Trial Research Agreement (“Agreement”) is entered into as of the publishing of this executed Agreement in Agreement Registry (“Effective Date”), by and among University Hospital Brno, Jihlavská 20, 625 00 Brno, Czech Republic, ID number: 65269705, VAT: CZ65269705, represented by: MUDr. Roman Kraus, MBA, Director, state- funded organization established by the decision of the Ministry of Health, without duty of registration in the commercial register, registered in the Trade Register kept by the Municipal Trade Office in Brno, (“Institution”), xxxxxxxx, Domicil: xxxxxxx, Born on: xxxxxxxxxxx, ( “Principal Investigator”) and Acerta Pharma B.V., a Dutch limited liability company, with registered office at xxxxxxxxxx, represented by duly authorized representative(s) of Acerta Pharma B.V. (“Acerta”) (“Sponsor”). The Institution, Principal Investigator and Sponsor are hereinafter individually referred t
